title: Myelodysplastic syndromes: clinical practice guidelines in oncology.
abstract: The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.
authors.affiliation: Stanford Cancer Institute, USA.
authors.forename: Peter L
authors.initials: PL
authors.lastname: Greenberg
authors.forename: Eyal
authors.initials: E
authors.lastname: Attar
authors.forename: John M
authors.initials: JM
authors.lastname: Bennett
authors.forename: Clara D
authors.initials: CD
authors.lastname: Bloomfield
authors.forename: Uma
authors.initials: U
authors.lastname: Borate
authors.forename: Carlos M
authors.initials: CM
authors.lastname: De Castro
authors.forename: H Joachim
authors.initials: HJ
authors.lastname: Deeg
authors.forename: Olga
authors.initials: O
authors.lastname: Frankfurt
authors.forename: Karin
authors.initials: K
authors.lastname: Gaensler
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Steven D
authors.initials: SD
authors.lastname: Gore
authors.forename: David
authors.initials: D
authors.lastname: Head
authors.forename: Rami
authors.initials: R
authors.lastname: Komrokji
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Maness
authors.forename: Michael
authors.initials: M
authors.lastname: Millenson
authors.forename: Margaret R
authors.initials: MR
authors.lastname: O'Donnell
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Shami
authors.forename: Brady L
authors.initials: BL
authors.lastname: Stein
authors.forename: Richard M
authors.initials: RM
authors.lastname: Stone
authors.forename: James E
authors.initials: JE
authors.lastname: Thompson
authors.forename: Peter
authors.initials: P
authors.lastname: Westervelt
authors.forename: Benton
authors.initials: B
authors.lastname: Wheeler
authors.forename: Dorothy A
authors.initials: DA
authors.lastname: Shead
authors.forename: Maoko
authors.initials: M
authors.lastname: Naganuma
mesh_terms: D000740:Anemia / Q000209:etiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000628:therapy; D011379:Prognosis; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D007155:Immunologic Factors